| Oral, Insufflated, Rectal|
CA: Schedule I
UK: Class B
Illegal in China
5-MAPB (1-(benzofuran-5-yl)-N-methylpropan-2-amine) is an entactogenic designer drug similar to MDMA on its structure and effects.
5-MAPB is not listed itself in the CDSA but since it is structurally related to MDMA it would be considered illegal in Canada.
As of October 2015 5-MAPB is a controlled substance in China.
5-MAPB was originally banned in the UK in June 2013 under a Temporary class drug order. On March 5, 2014 the UK Home Office announced that 5-MAPB would be made a class B drug on 10 June 2014 alongside every other benzofuran entactogen and many structurally related drugs.
Little formal knowledge exists on 5-MAPB. It does not share the neurotoxicity of MDA caused by the alpha-methyldopamine metabolite. A study in rats indicated that the major metabolites of 5-MAPB are 5-APB and 3-carboxymethyl-4-hydroxymethamphetamine.
5-MAPB binds to the dopamine transporter in rat brain cells with a lower potency than cocaine. In silico data suggests that the primary action on dopamine is through reversal of the transporter to release dopamine. This is consistent with the effects and it is likely that it exerts a similar action on serotonin and norepinephrine transporters.